close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.889 +0.109 (+3.92%)
Streaming Delayed Price Updated: 10:06 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Here are the top movers in Wednesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Analysts Have This To Say About Editas Medicine ↗
 
Via Benzinga
News headline image
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Where Editas Medicine Stands With Analysts ↗
 
Via Benzinga
News headline image
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution ↗
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines. 
Via Benzinga
News headline image
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 ↗
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing. 
Via Benzinga
News headline image
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30 ↗
Via Talk Markets
Topics Stocks / Equities
News headline image
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
News headline image
Looking for Stock Bargains With Room to Run? Try This. ↗
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition ↗
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
News headline image
3 Profitable CRISPR Stocks Earning Analysts’ Praise ↗
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today